Bausch Health's BRYHALI(TM) (halobetasol propionate) Lotion, 0.01%, Receives Tentative FDA Approval For Plaque Psoriasis In Adults

In Clinical Trials, BRYHALI Lotion Demonstrated Significant Treatment Success Over Vehicle as Early as Week Two, Which Continued Through Week 12 (Four Weeks Post Treatment)1 New Corticosteroid Lotion Formulation with Safety Proven for Up to Eight Weeks... Biopharmaceuticals, Dermatology, FDA Bausch Health, BRYHALI, halobetasol, Plaque Psoriasis, Psoriasis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news